Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Treatment of EGFR mutant-related cancers using a combination of EGFR and CDK4/6 inhibitors

Treatment of EGFR mutant-related cancers using a combination of EGFR and CDK4/6 inhibitors

US Patent 12390464 · Granted Aug 19, 2025

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Protein degradation agent compound preparation method and application2025
Organophosphorus-substituted compounds as c-MET inhibitors and therapeutic uses 2025
Organophosphorus-substituted compounds as c-MET inhibitors and therapeutic uses 2025
Organophosphorus-substituted compounds as c-MET inhibitors and therapeutic uses 2025
Organophosphorus-substituted compounds as c-MET inhibitors and therapeutic uses 2025
Organophosphorus-substituted compounds as c-MET inhibitors and therapeutic uses 2025
Pharmaceutical formulations of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(12025
Pharmaceutical formulations of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(12025
Pharmaceutical formulations of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(12025
Pharmaceutical formulations of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(12025
Pharmaceutical formulations of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(12025
Substituted 2-anilinopyrimidine derivatives as EGFR modulators2022